Cervical dysplasia is the presence of abnormal cells on the surface of the cervix, the narrow passage connecting the uterus to the vagina. These cells aren’t cancer, but depending on how abnormal they are, they have the potential to become cancer over time if left untreated. Nearly all cases are caused by persistent infection with certain strains of human papillomavirus (HPV), and the condition is detected through routine screening like Pap smears and HPV tests.
How Cervical Dysplasia Develops
The cervix is lined with a thin layer of cells that normally grow, divide, and replace themselves in an orderly pattern. When high-risk strains of HPV infect these cells, the virus produces proteins that disable two of the body’s key tumor-suppressing mechanisms. One viral protein binds to and destroys a molecule called p53, which normally triggers damaged cells to self-destruct. Another disables a protein that acts as a brake on cell division. With both safeguards knocked out, infected cells begin multiplying in an uncontrolled way.
This doesn’t happen overnight. Most HPV infections clear on their own within one to two years. Dysplasia develops when the immune system fails to clear the virus and the infection persists, giving those viral proteins time to accumulate genetic damage in cervical cells. The result is a patch of abnormal tissue that can be mild and self-limiting or, in some cases, progressively more disorganized.
Grades of Cervical Dysplasia
When a biopsy is taken from the cervix, the abnormal changes are classified using a system called cervical intraepithelial neoplasia, or CIN, graded 1 through 3 based on how deeply the abnormal cells extend into the tissue lining.
- CIN 1 (mild dysplasia): Abnormal cells are confined to the lower third of the cervical lining. This is considered low-grade and usually resolves on its own without treatment. It is commonly associated with low-risk HPV types.
- CIN 2 (moderate dysplasia): Abnormal cells extend into the middle third of the lining. This is a gray zone. Some CIN 2 lesions regress spontaneously, particularly in younger women, while others progress.
- CIN 3 (severe dysplasia): Abnormal cells occupy the full thickness of the lining but have not broken through to deeper tissue. This is the stage closest to early cancer and is the most likely to require treatment.
The distinction matters because progression rates differ significantly by grade. Roughly 10% of CIN 1 cases progress to CIN 3, compared to about 20% of CIN 2 cases. At least 12% of CIN 3 cases eventually progress to invasive cervical cancer if untreated. These numbers also mean the majority of low-grade cases never become dangerous.
Who Gets It and Why
There are 12 high-risk HPV types, but two of them, HPV 16 and HPV 18, are responsible for most HPV-related cancers. These high-risk strains are found in 50 to 80% of moderate and severe dysplasia cases and in 90% of cervical cancers. HPV is extremely common and spreads through skin-to-skin sexual contact, so most sexually active people will be infected at some point. The infection itself is not the problem. The problem is when it doesn’t go away.
Several factors increase the risk of persistent HPV infection and, by extension, dysplasia. Smoking is one of the strongest. A weakened immune system, whether from HIV, organ transplant medications, or other causes, also makes it harder to clear the virus. Having multiple sexual partners increases exposure, and long-term use of oral contraceptives has been linked to a modestly higher risk, though the reasons aren’t entirely clear. Having other sexually transmitted infections alongside HPV may also play a role.
How It’s Found
Cervical dysplasia causes no symptoms. You won’t feel it, and it doesn’t cause pain, bleeding, or discharge on its own. It’s detected through screening: a Pap smear (which looks for abnormal cells), an HPV test (which checks for high-risk virus strains), or both done together.
If screening results come back abnormal, the next step is typically a colposcopy. During this procedure, a clinician uses a magnifying instrument to closely examine the cervix after applying a vinegar-like solution that makes abnormal areas turn white. If suspicious patches are visible, a small tissue sample (biopsy) is taken. You may feel a pinch or brief cramping during the biopsy. Taking an over-the-counter pain reliever beforehand can help. A separate sample may also be collected from the cervical canal using a small scraping tool, called endocervical curettage, to check for abnormalities higher up where the magnifying instrument can’t see.
The biopsy results determine the CIN grade and guide what happens next.
When Dysplasia Resolves on Its Own
Not all dysplasia needs treatment. A significant portion of cases, especially lower-grade ones, regress without any intervention. In one study tracking 114 women with CIN 2 or CIN 3 under close monitoring, clinical regression occurred in 67 of them. Roughly two-thirds of the group ultimately avoided surgical treatment altogether. None developed cervical cancer during the observation period.
This is why current guidelines use a risk-based approach rather than treating every abnormal result. For young women with CIN 1 or even CIN 2, watchful waiting with repeat testing at set intervals is often preferred. Treatment carries its own costs: procedures on the cervix can affect its structure, and in some cases increase the risk of preterm birth in future pregnancies. Keeping overtreatment to a minimum is a specific goal of current management strategies.
That said, watchful waiting only works with reliable follow-up. If you’re being monitored, keeping those appointments is essential.
Treatment Options
When dysplasia is high-grade, persistent, or progressing, treatment removes or destroys the abnormal tissue. The two most common approaches are excisional procedures, which cut out the affected area, and ablative procedures, which destroy the tissue in place.
Excisional Procedures
The most widely used excisional method is a loop procedure (often called LEEP), which uses a thin, electrically heated wire loop to remove a disc-shaped piece of cervical tissue. It’s done in a clinic under local anesthesia, takes about 10 to 20 minutes, and most people return to normal activities within a few days. The removed tissue is sent to a lab, which allows pathologists to check whether the edges of the sample are clear of abnormal cells.
A cone biopsy (cold knife conization) removes a larger, cone-shaped piece of tissue and is typically done in an operating room, sometimes under general anesthesia. It’s used when a deeper or wider sample is needed. Both procedures are equally effective at clearing dysplasia, with no significant difference in recurrence rates. The loop procedure has practical advantages: no general anesthesia, lower cost, fewer complications, and reduced risk of obstetric problems afterward. However, the heat from the wire can sometimes distort the edges of the tissue sample, making it harder for the pathologist to confirm clean margins.
Ablative Procedures
Cryotherapy freezes the abnormal tissue using a probe applied to the cervix, typically with a freeze-thaw-freeze cycle lasting about 11 minutes total. Thermal ablation uses a heated probe instead. These methods are simpler and less expensive than excision, but they don’t produce a tissue sample for further analysis, so they’re only appropriate when the full extent of the abnormality is clearly visible and biopsy has already confirmed the diagnosis.
Follow-Up After Treatment
Treatment is highly effective, but dysplasia can recur, especially if the underlying HPV infection persists. Current guidelines recommend continued surveillance testing for at least 25 years after treatment for cervical precancer. This typically involves a combination of Pap smears and HPV testing at intervals determined by your risk level. The long surveillance window reflects the fact that recurrence can happen years or even decades later.
There is some evidence that HPV vaccination after treatment may reduce the chance of recurrence. One study found that women who received the vaccine around the time of their procedure had a significantly lower rate of high-grade abnormalities at follow-up (2.6%) compared to unvaccinated women (10.5%). However, results across studies have been mixed, and vaccination after treatment is not yet a universal recommendation.
Prevention Through Vaccination and Screening
The HPV vaccine protects against the high-risk strains most likely to cause dysplasia and cervical cancer, including HPV 16 and 18 along with seven other high-risk types. Vaccination is most effective when given before any exposure to HPV, which is why it’s recommended for preteens, but it’s approved for people up to age 45. It prevents the initial infection that starts the entire chain of events leading to dysplasia.
Screening remains critical even for vaccinated individuals because the vaccine doesn’t cover every high-risk HPV strain. Routine screening with Pap smears and HPV testing, starting at age 21 or 25 depending on the guidelines your provider follows, catches abnormalities early when they’re most manageable. The combination of vaccination and regular screening has made cervical cancer one of the most preventable cancers.